Table 2.
Prognostic factors associated with HCC recurrence
| Variable | Comparison | Univariable | Multivariable | ||
|---|---|---|---|---|---|
|
|
|
||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age (years) | > 60 vs. ≤ 60 | 1.39 (1.06-1.83) | 0.018 | 1.49 (1.11-1.99) | 0.008 |
| Sex | Male vs. Female | 1.09 (0.76-1.57) | 0.624 | ||
| Hypertension | Yes vs. No | 1.20 (0.91-1.60) | 0.203 | ||
| Diabetes mellitus | Yes vs. No | 1.50 (1.11-2.03) | 0.008 | ||
| BMI (kg/m2) | ≥ 23 vs. < 23 | 0.80 (0.59-1.07) | 0.134 | ||
| AFP (ng/mL) | ≥ 10 vs. < 10 | 1.54 (1.11-2.15) | 0.010 | 1.55 (1.10-2.18) | 0.013 |
| Platelet (103/µL) | < 150 vs. ≥ 150 | 1.32 (0.99-1.76) | 0.052 | ||
| Liver cirrhosis | Yes vs. No | 2.13 (1.60-2.83) | < 0.001 | 1.99 (1.47-2.70) | < 0.001 |
| HBV DNA (IU/mL) | ≥ 2000 vs. < 2000 | 1.12 (0.65-1.63) | 0.920 | ||
| NUCs treatment | Yes vs. No | 0.96 (0.72-1.26) | 0.745 | ||
| BCLC stage | A vs. 0 | 1.62 (1.16-2.28) | 0.005 | ||
| Tumor size (cm) | ≥ 2 vs. < 2 | 1.57 (1.11-2.22) | 0.012 | 1.59 (1.10-2.29) | 0.014 |
| Tumor number | Multiple vs. Single | 1.47 (1.02-2.11) | 0.040 | 1.50 (1.02-2.19) | 0.037 |
| MVI | Yes vs. No | 1.16 (0.86-1.56) | 0.326 | ||
| MASLD | Yes vs. No | 0.97 (0.74-1.28) | 0.843 | ||
HR, hazard ratio; CI, confidence interval; AFP, alpha fetoprotein; BMI, body mass index; NUCs, nucleos(t)ide analogs; MVI, microvascular invasion; MASLD, metabolic dysfunction-associated steatotic liver disease.